8-K: Tonix Pharmaceuticals Awarded Grant for Mpox and Smallpox Vaccine Development; Shows Promising TNX-801 Data

Tonix Pharmaceuticals receives a $50,000 grant to advance its TNX-801 vaccine candidate and unveils new data highlighting its safety and efficacy.

Summary

• Tonix Pharmaceuticals announced it received a $50,000 grant from the Medical CBRN Defense Consortium (MCDC) to support the development of TNX-801, a recombinant horsepox virus vaccine candidate for mpox and smallpox.
• The grant will facilitate the development of a commercialization plan for TNX-801.
• The company also disclosed new data indicating that TNX-801 is significantly less virulent than traditional smallpox vaccines in immunocompromised mice, is deliverable via alternative routes, and provides durable protection to rabbits against a lethal rabbitpox challenge for over six months.
• TNX-801 is designed as a single-dose vaccine with favorable shipping and storage requirements.
• The World Health Organization (WHO) has reaffirmed the spread of new clade Ib Mpox as a public health emergency of international concern.
• Clade Ib Mpox cases have been detected in several countries, including those in Central and Eastern Africa, China, Thailand, Singapore, India, England, parts of Europe and the Middle East, Canada, and the United States.

Sentiment

Score: 8

Explanation: The document presents positive news regarding a grant award and promising data for TNX-801, suggesting a favorable outlook for the company's vaccine development program. The focus on safety and efficacy, along with the single-dose design, contributes to a positive sentiment.

Positives

• The $50,000 grant from MCDC will help Tonix develop a commercialization plan for TNX-801.
• TNX-801 has shown promising safety and efficacy data in animal models.
• TNX-801 is significantly less virulent than traditional smallpox vaccines, potentially leading to fewer side effects.
• The vaccine can be delivered via alternative routes, improving patient compliance and ease of use.
• TNX-801 offers durable, long-term protection with a single dose.

Risks

• The development of TNX-801 is subject to the risks inherent in pharmaceutical development, including clinical trial failures and regulatory hurdles.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.
• The company faces competition in the vaccine market.
• The company may require additional financing to continue its development programs.

Future Outlook

The company intends to place the updated TNX-801 product candidate presentation on its website and plans to continue the development of TNX-801 as a potential vaccine for mpox and smallpox.

Management Comments

• Seth Lederman, M.D., President, and Chief Executive Officer of Tonix, stated, 'We are excited by the opportunity to collaborate with MCDC and are thankful for their support of our vaccine candidate.'

Industry Context

The announcement comes amid ongoing concerns about the spread of mpox, with the WHO reaffirming it as a public health emergency of international concern, highlighting the need for effective vaccines and treatments.

Comparison to Industry Standards

• The document mentions ACAM2000 (Emergent) and Jynneos (Bavarian Nordic) as two FDA-approved vaccines for smallpox and mpox.
• ACAM2000 is a live-virus vaccine with tolerability concerns, while Jynneos is a non-replicating vaccine requiring a two-dose regimen.
• TNX-801 aims to offer a single-dose alternative with improved tolerability compared to ACAM2000 and potentially better efficacy than Jynneos.
• The presentation references the historical context of Edward Jenner's horsepox vaccine and its relationship to modern vaccinia strains, suggesting TNX-801 is designed to recapture the benefits of early vaccines with modern manufacturing and safety standards.
• The document references the use of vaccinia-based vaccines for rabies control, specifically RABORAL V-RG, which has been distributed aerially in several countries, demonstrating the feasibility of widespread poxvirus vaccine deployment.

Stakeholder Impact

• Positive for shareholders due to the grant and promising vaccine data.
• Potential benefit to public health by providing a safer and more effective vaccine against mpox and smallpox.
• May improve the medical readiness of military personnel in biological threat environments.

Next Steps

• Tonix plans to develop a commercialization plan for TNX-801.
• The company will continue to evaluate the tolerability and activity of TNX-801 in animal models.
• Tonix intends to place the updated TNX-801 product candidate presentation on its website.

Key Dates